Previous Close | 0.0300 |
Open | 0.0300 |
Bid | 0.0000 |
Ask | 0.0800 |
Strike | 70.00 |
Expire Date | 2024-06-21 |
Day's Range | 0.0300 - 0.0300 |
Contract Range | N/A |
Volume | |
Open Interest | 1.89k |
Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine Comirnaty and the treatment Paxlovid -- saw its shares drop about 40%. This includes Pfizer's newer programs and what they may deliver in the future, as well as the company's valuation today. Is Pfizer a buy right now -- or a stock to avoid?
One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). Here are two other issues driving me toward hitting the "sell" button on this pharma stock. Since Albert Bourla took over as CEO in 2019, Pfizer has been on a buying spree.
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.